|
**Overview**: **Allergy Post Screening Profile****Introduction**: The Allergy Post Screening Profile is a diagnostic tool designed to conduct follow-up allergy screening using serum samples. Associated with allergic disorders like asthma, eczema, and food allergies, these conditions present with varied symptoms such as itching, respiratory distress, and severe complications if untreated, particularly in individuals with prior allergen exposure. Per the 2023 American Academy of Allergy, Asthma & Immunology guidelines, the test employs allergology with immunoassay technology, delivering detailed allergen identification over 1-2 days with high sensitivity and specificity, making it a valuable tool for allergy follow-up in clinical settings. This diagnostic falls under allergy follow-up and targets individuals with previous allergic diagnoses, addressing the challenge of monitoring allergen sensitivity to guide ongoing management or treatment adjustments. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Post Screen Pfl.**FDA Status**: FDA approved, CLIA certified for allergology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by various allergy labs, this test advanced allergy management by providing follow-up diagnostics.**Purpose**: The test screens for 32 allergens including total IgE and grass pollen to guide allergy assessment, assess immune response, and inform treatment and prevention strategies.**Test Parameters**: 1. Total IgE, 2. Grass Pollen (Timothy), 3. Tree Pollen (Birch), 4. Weed Pollen (Ragweed), 5. Dust Mite (D. pteronyssinus), 6. Dust Mite (D. farinae), 7. Cat Dander, 8. Dog Dander, 9. Cockroach, 10. Mold (Alternaria), 11. Mold (Aspergillus), 12. House Dust, 13. Milk, 14. Egg White, 15. Wheat, 16. Soybean, 17. Peanut, 18. Fish (Cod), 19. Shrimp, 20. Almond, 21. Cashew, 22. Apple, 23. Banana, 24. Orange, 25. Mango, 26. Tomato, 27. Potato, 28. Carrot, 29. Celery, 30. Spinach, 31. Latex, 32. Candida albicans.**Pretest Condition**: No fasting required; patients should avoid antihistamines and report varied symptoms or recent allergen exposure.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on varied symptoms, prior allergic reactions, or family history of allergies, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated allergies including anaphylaxis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antihistamine use can affect results. Correlation with clinical evaluation or previous test results is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible ongoing allergic sensitivities, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in evolving sensitization stages.**Specialist Consultation**: General practitioners or specialists in allergology or immunology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Skin prick test, specific IgE levels, or challenge testing for confirmation.**Test Limitations**: The test may produce false negatives in early sensitization or false positives in cross-reactive conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: AAAAI Guidelines 2023, Journal of Allergy and Clinical Immunology 2024, Allergology 2025. |
